Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Kronos Bio Inc
KRONKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. Address: 1300 So. El Camino Real, San Mateo, CA, United States, 94402
Analytics
Precio Objetivo de WallStreet
2.25 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave KRON
Análisis de dividendos KRON
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout KRON
Valoración de la acción KRON
Finanzas KRON
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |